PhaseBio Pharmaceuticals, Inc. Stock

PHAS.Q

US7172241090

OTC Markets Traded

Latest news : PhaseBio Pharmaceuticals, Inc.

24-09-30	PhaseBio Pharmaceuticals, Inc. Went Out of Business	CI
24-06-26	First Amended Combined Liquidation Plan and Disclousre Statement Approved on Final Basis for PhaseBio Pharmaceuticals, Inc.	CI
24-05-13	Amended Disclosure Statement Conditionally Approved for PhaseBio Pharmaceuticals, Inc.	CI
24-04-19	First Amended Combined Liquidation Plan and Disclousre Statement Filed by PhaseBio Pharmaceuticals, Inc.	CI
24-02-07	Fifth Motion for Exclusivity Period Extension Approved For PhaseBio Pharmaceuticals, Inc.	CI
23-11-07	Fourth Motion for Exclusivity Period Extension Approved For PhaseBio Pharmaceuticals, Inc.	CI
23-10-03	PhaseBio Pharmaceuticals, Inc. Announces Resignation of Caroline Loewy as Member of the Board of Directors	CI
23-09-07	Third Motion for Exclusivity Period Extension Approved For PhaseBio Pharmaceuticals, Inc.	CI
23-08-01	Modified Combined Disclosure Statement Approved on Interim Basis for PhaseBio Pharmaceuticals, Inc.	CI
23-07-10	Second Motion for Exclusivity Period Extension Approved For PhaseBio Pharmaceuticals, Inc.	CI
23-07-07	Combined Liquidation Plan and Disclousre Statement Filed by PhaseBio Pharmaceuticals, Inc.	CI
23-03-13	First Motion for Exclusivity Period Extension Approved For PhaseBio Pharmaceuticals, Inc.	CI
23-02-16	First Motion for Exclusivity Period Extension Filed by PhaseBio Pharmaceuticals, Inc.	CI

More news

Analysts' recommendations: PhaseBio Pharmaceuticals, Inc.

22-10-25	Cowen Downgrades PhaseBio Pharmaceuticals to Market Perform From Outperform	MT
22-09-28	Stifel Nicolaus Downgrades PhaseBio Pharmaceuticals to Hold From Buy, Sets $1 Price Target	MT
22-09-28	Needham Downgrades PhaseBio Pharmaceuticals to Hold from Buy	MT
22-09-28	William Blair Downgrades PhaseBio Pharmaceuticals to Market Perform From Outperform	MT
22-08-15	Needham Adjusts Price Target on PhaseBio Pharmaceuticals to $8 From $10, Reiterates Buy Rating	MT

More recommendations

Press Releases: PhaseBio Pharmaceuticals, Inc.

22-10-31	PHASEBIO PHARMACEUTICALS INC : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ
22-10-24	PHASEBIO PHARMACEUTICALS INC : Bankruptcy or Receivership, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
22-10-24	PhaseBio Plans for Near-Term Sale Using Structured Process Through Chapter 11 of U.S. Bankruptcy Code	BU
22-10-07	PHASEBIO PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant (form 8-K)	AQ
22-09-27	PHASEBIO PHARMACEUTICALS INC : Other Events (form 8-K)	AQ

More press releases

News in other languages: PhaseBio Pharmaceuticals, Inc.

19-04-09	Dow Jones Industrial Average : Les valeurs à suivre à Wall Street
19-04-09	USA-Les valeurs à suivre à Wall Street (actualisé)
19-03-18	Dow Jones Industrial Average : Les valeurs à suivre à Wall Street
19-03-18	USA-Les valeurs à suivre à Wall Street (actualisé)

More news

Managers and Directors: PhaseBio Pharmaceuticals, Inc.

Manager	Title	Age	Since
Jonathan Mow CEO	Chief Executive Officer	61	2014-08-31
Lawrence Perkins DFI	Director of Finance/CFO	49	2022-11-29
John Lee CTO	Chief Tech/Sci/R&D Officer	58	2016-04-17

Director	Title	Age	Since
Clay Thorp CHM	Chairman	57	2014-10-31
Jonathan Mow BRD	Director/Board Member	61	2014-08-31
Richard van den Broek BRD	Director/Board Member	60	2019-02-26

More insiders

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel therapies for cardiovascular diseases. Its lead product candidate, bentracimab (also known as PB2452), is a novel reversal agent for the antiplatelet drug ticagrelor. Ticagrelor is an antiplatelet therapy widely prescribed to reduce the rates of death, heart attack and stroke in patients with acute coronary syndrome (ACS), or who have previously experienced a heart attack. Ticagrelor binds to platelets to prevent them from forming blood clots that could restrict blood flow. The Company is also developing its preclinical product candidate, PB6440, an oral selective aldosterone synthase inhibitor for treatment-resistant hypertension. The Company is leveraging ELP biopolymer technology to evaluate additional preclinical and discovery-stage candidates. Its focus is on proteins and peptides that are scientifically or clinically validated.

Employees

Sector

More about the company

Date	Insider	Type	Main position	Quantity	% Market Cap.
23-05-18	Alexander Sapir	Fiscal year	Director	7,500	0.0150%
23-05-18	William Humphries	Fiscal year	Director	5,076	0.0102%
23-05-18	Hatteras Venture Partners	Fiscal year	Company	7,500	0.0150%